In analysis, baseline INSTI resistance and baseline viral load were highly significant predictors for week 24 response. For each two-fold increase in DTG fold-change, a 63% lower chance of achieving viral load ,50 copies/mL was found. For every 10-fold increase in baseline viral load, the odds of achieving viral load ,50 copies/mL were 80% lower. The median change in CD4 cell count at week 24 was 61 cells/mm3. Secondary outcomes included efficacy at week 48 and have only been presented in abstract form thus far. At week 48, 116/183 (63%) patients maintained a viral load ,50 copies/mL. Again the subgroup with no Q148 mutation present had the highest response rate with 71% achieving ,50 copies/mL at week 48.